Assessing the metabolic effects of prednisolone in healthy volunteers using urine metabolic profiling.

ABSTRACT:

Background

Glucocorticoids, such as prednisolone, are widely used anti-inflammatory drugs, but therapy is hampered by a broad range of metabolic side effects including skeletal muscle wasting and insulin resistance. Therefore, development of improved synthetic glucocorticoids that display similar efficacy as prednisolone but reduced side effects is an active research area. For efficient development of such new drugs, in vivo biomarkers, which can predict glucocorticoid metabolic side effects in an early stage, are needed. In this study, we aim to provide the first description of the metabolic perturbations induced by acute and therapeutic treatments with prednisolone in humans using urine metabolomics, and to derive potential biomarkers for prednisolone-induced metabolic effects.

SUBMITTER: Ellero-Simatos S 

PROVIDER: S-EPMC4064315 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature